Impact of Angiotensin II Signaling Blockade on Clinical Outcomes in Patients with Inflammatory Bowel Disease

@article{Jacobs2019ImpactOA,
  title={Impact of Angiotensin II Signaling Blockade on Clinical Outcomes in Patients with Inflammatory Bowel Disease},
  author={Jeffrey Daniel Jacobs and Thomas Wagner and George Gulotta and Chuanhong Liao and Yan Chun Li and Marc R. Bissonnette and Joel R Pekow},
  journal={Digestive Diseases and Sciences},
  year={2019},
  volume={64},
  pages={1938-1944}
}
BackgroundPreclinical data demonstrate that activation of the renin–angiotensin system (RAS) contributes to mucosal inflammation, and RAS inhibition by angiotensin-converting-enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) improves colitis in animal models. Less is known regarding the effects of RAS inhibition on clinical outcomes in inflammatory bowel disease (IBD) patients.AimEvaluate the impact of ACEI and ARB on clinical outcomes in IBD.MethodsRates of IBD-related… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 28 REFERENCES

to suppress the pathogenesis of acute colitis induced by dextran sulphate sodium

Guerra GCB, AA Araújo, GA Lira
  • 2015

Losartan reduces trinitrobenzene sulphonic acid-induced colorectal fibrosis in rats.

  • Canadian journal of gastroenterology = Journal canadien de gastroenterologie
  • 2012
VIEW 1 EXCERPT